Reviewer's report

Title: Survival of Gastrointestinal Stromal Tumor Patients in the Imatinib era: Life Raft Group Observational Registry

Version: 2 Date: 21 December 2011

Reviewer: Philippe Cassier

Reviewer's report:

No major revision
Minor essential revision: although the cover letter states that "The references to "wild-type mutations" were correcte", the 3rd line of the last paragraph of page 7, still refers to wild type mutations.

Discretionary revision: I still think the introduction could be shortened a bit more. As the authors have made no comments on the total number of patients tested for the different exons of KIT (all patients tested), PDGFRA, BRAF and SDH (patients from the NIH), I'm assuming this is unknown and think it would proabably be worth mentioning that the denominator for the less common mutations (PDGRA, BRAF and SDH) is unknown.

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.